Spoilt for choice: different immunosuppressive potential of anaplastic lymphoma kinase inhibitors for non small cell lung cancer

INTRODUCTION: Several anaplastic lymphoma kinase (ALK)-inhibitors (ALKi) have been approved for the treatment of ALK-translocated advanced or metastatic Non Small Cell Lung Cancer (NSCLC), amongst crizotinib and alectinib. This forces physicians to choose the most suitable compound for each individu...

Descripción completa

Detalles Bibliográficos
Autores principales: Heine, Annkristin, Held, Stefanie Andrea Erika, Daecke, Solveig Nora, Flores, Chrystel, Brossart, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562553/
https://www.ncbi.nlm.nih.gov/pubmed/37822928
http://dx.doi.org/10.3389/fimmu.2023.1257017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562553/
https://www.ncbi.nlm.nih.gov/pubmed/37822928
http://dx.doi.org/10.3389/fimmu.2023.1257017

Ejemplares similares